Cullinan Management, Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Management, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2021
Exchange: NASDAQ
Website: cullinanoncology.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/11/2025 | $22.00 | Buy | Stifel |
| 10/24/2024 | $30.00 | Buy | UBS |
| 5/1/2024 | $40.00 | Buy | Stifel |
| 4/15/2024 | Outperform | William Blair | |
| 2/15/2024 | $30.00 | Outperform | Wedbush |
| 6/15/2023 | Outperform | TD Cowen | |
| 11/21/2022 | $20.00 | Buy | BTIG Research |
8-K - Cullinan Therapeutics, Inc. (0001789972) (Filer)
8-K - Cullinan Therapeutics, Inc. (0001789972) (Filer)
10-Q - Cullinan Therapeutics, Inc. (0001789972) (Filer)
8-K - Cullinan Therapeutics, Inc. (0001789972) (Filer)
DEFA14A - Cullinan Therapeutics, Inc. (0001789972) (Filer)
DEF 14A - Cullinan Therapeutics, Inc. (0001789972) (Filer)
S-8 - Cullinan Therapeutics, Inc. (0001789972) (Filer)
10-K - Cullinan Therapeutics, Inc. (0001789972) (Filer)
8-K - Cullinan Therapeutics, Inc. (0001789972) (Filer)
8-K - Cullinan Therapeutics, Inc. (0001789972) (Filer)
Stifel resumed coverage of Cullinan Therapeutics with a rating of Buy and set a new price target of $22.00
UBS initiated coverage of Cullinan Therapeutics with a rating of Buy and set a new price target of $30.00
Stifel initiated coverage of Cullinan Management with a rating of Buy and set a new price target of $40.00
William Blair initiated coverage of Cullinan Management with a rating of Outperform
Wedbush initiated coverage of Cullinan Management with a rating of Outperform and set a new price target of $30.00
TD Cowen initiated coverage of Cullinan Management with a rating of Outperform
BTIG Research initiated coverage of Cullinan Management with a rating of Buy and set a new price target of $20.00
Morgan Stanley reiterated coverage of Cullinan Oncology with a rating of Overweight and set a new price target of $43.00 from $40.00 previously
HC Wainwright & Co. reiterated coverage of Cullinan Oncology with a rating of Buy and set a new price target of $55.00 from $48.00 previously
SVB Leerink reiterated coverage of Cullinan Oncology with a rating of Outperform and set a new price target of $54.00 from $48.00 previously